Ron Panzier

Great Point seeks to achieve positive excess returns by investing in publicly traded biotechnology, pharmaceutical and life science companies. The firm focuses on creating a balanced portfolio comprised primarily of companies that are undervalued by the public markets. Their hedge funds employ a bottom-up research-driven approach to investing in the securities of undervalued, publicly-traded healthcare companies. Great Point Partners targets fast-growing, technology- driven small-cap companies. In addition, the firm manages private equity funds that invest in private, primarily profitable, lower middle-market, growing healthcare companies.

ReachCapital invests long/short. They target European mid-cap opportunities.

Provides auditing, financial advisory and tax consulting services

Functions as a College/University

Great Point Partners invests in companies located in the United States, Canada and Western Europe with an EBITDA ranging from USD 2 - 12 million and revenue ranging from USD 10 - 100 million. The firm targets companies operating in the fields of healthcare sectors and industries. It provides financing for buyout and growth capital requirements with an investment size ranging from USD 10 - 100 million. The firm acquires minority and majority interests and also acts as lead investor.